Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180961 | 0.84 | L3MBTL1 (0.34) | L3MBTL1F2CA14 | |
| SCHEMBL6965307 | 0.83 | L3MBTL1 (0.32) | L3MBTL1SLC2A1KDM4ETDP1 | |
| SCHEMBL6177046 | 0.81 | L3MBTL1 (0.32) | L3MBTL1F2 | |
| SCHEMBL6094085 | 0.79 | CCR6 (0.43) | L3MBTL1TDP1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5805153 | 0.77 | SMN1; SMN2 (0.49) | L3MBTL1F2KMT2AMEN1CYP3A4 | |
| SCHEMBL6174342 | 0.74 | ITGB3 (0.45) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2798824 | 0.73 | SMN1; SMN2 (0.47) | L3MBTL1F2KMT2AMEN1CYP3A4 | |
| SCHEMBL31499054 | 0.73 | BCL2A1 (0.38) | L3MBTL1SSTR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL20025128 | 0.72 | POLB (0.47) | SSTR4F2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1241389 | 0.69 | LSS (0.40) | SSTR4KDM4EF2CA14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| US-20020123487-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| US-20020019387-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-02-14 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| EP-1023073-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999015178-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | L3MBTL1 4279/4885SSTR4 998/4885SLC2A1 3673/4885 |
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | L3MBTL1 4796/4885SSTR4 739/4885SLC2A1 2436/4885 |
| US-20020123487-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | L3MBTL1 4746/4885SSTR4 671/4885SLC2A1 2433/4885 |
| US-20020019387-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | L3MBTL1 4746/4885SSTR4 671/4885SLC2A1 2433/4885 |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | L3MBTL1 4658/4885SSTR4 864/4885SLC2A1 2723/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | L3MBTL1 4279/4885SSTR4 998/4885SLC2A1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.